Showing results (2111-2120 of 2,126) with videos related to

Sort By:
Pageof 213
Physical Review Letters|June 13, 2009
Isotopic dependence of the nuclear caloric curveC Sfienti, P Adrich, T Aumann, et al.
Annals of Surgical Oncology|August 3, 2026
Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy on the I-SPY2 TrialJ Tseng, K Dimitroff, C A M Sauder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2020
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 TrialA Jo Chien, Debasish Tripathy, Kathy S Albain, et al.
Science (New York, N.Y.)|January 23, 2010
The genetic landscape of a cellMichael Costanzo, Anastasia Baryshnikova, Jeremy Bellay, et al.
Nature Communications|November 6, 2021
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trialAmy S Clark, Christina Yau, Denise M Wolf, et al.
NPJ Breast Cancer|December 1, 2022
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancerJulie E Lang, Andres Forero-Torres, Douglas Yee, et al.
ACS Central Science|November 2, 2016
Open Source Drug Discovery: Highly Potent Antimalarial Compounds Derived from the Tres Cantos ArylpyrrolesAlice E Williamson, Paul M Ylioja, Murray N Robertson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2023
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker DiscoveryKathy S Albain, Christina Yau, Emanuel F Petricoin, et al.
Science Advances|April 2, 2020
Slow slip source characterized by lithological and geometric heterogeneityPhilip M Barnes, Laura M Wallace, Demian M Saffer, et al.
JAMA Oncology|July 30, 2026
Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical TrialClaudine Isaacs, Rita Nanda, Christina Yau, et al.
Pageof 213